IL6 and breast cancer: While there has not been a comprehensive comparison of the downstream pathways activated by each ligand in breast cancer, many mechanistic studies have identified STAT3 as the key downstream mediator of IL-6 [127] and OSM [124,128,129] tumor-promoting effects.